Exactech’s Equinoxe® Stemless Shoulder Replacement System Debuts in Europe
Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that the first anatomic total shoulder surgery has been performed in Europe using its bone-conserving, 3D-printed Equinoxe® Stemless Shoulder. Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany, performed the first surgery earlier this month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210916005561/en/
Prof. Mark Tauber, MD, PhD, of Athos Klinik in Munich, Germany performed the first surgery in Europe using Exactech's bone-conserving, 3D-printed Equinoxe® Stemless Shoulder (Photo: Business Wire)
“It was wonderful to be the first user of the Exactech Stemless humeral component in Europe,” Tauber said. “I’ve used stemless implants with various systems since 2007, so I know what we are talking about and have to congratulate Exactech for this product. The user-friendly instrumentation and implant design features made a really convincing impression regarding primary stability.”
The Equinoxe Stemless Shoulder was introduced in the U.S. in 2018 and is manufactured using direct metal 3D printing with high precision lasers to create its porous bone cage. This humeral component’s bone cage structure is designed for initial press-fit and biologic fixation.
“We are thrilled to offer this innovative product to our European partners, surgeons and patients. We hope this implant helps many patients get back to what they love, and we look forward to supporting our sales team members and surgeon customers,” said Bruce Thompson, Exactech’s Senior Vice President of International Sales.
Additional features of the product include the humeral component's optimized pore size, count and porosity, as well as surgical efficiency through its single instrument tray. Surgeons can also use it in conjunction with the Equinoxe Shoulder System's standard and augmented glenoid solutions.
The Stemless Shoulder was designed with doctors Curtis Noel, of the Crystal Clinic in Akron, Ohio; Felix “Buddy” Savoie, of Tulane University in New Orleans, La.; Pierre-Henri Flurin, of Clinique du Sport in Bordeaux-Mérignac, France; Ryan Simovitch, of HSS Florida in West Palm Beach, Fla.; Thomas Wright, of the University of Florida, in Gainesville, Fla.; and Joseph Zuckerman, of NYU Langone Orthopaedic Hospital, in New York City.
Exactech plans to roll out additional inventory throughout the rest of 2021. Interested surgeons can learn more about the implant and its instrumentation at upcoming society shows throughout Europe or by visiting each country’s website:
- Germany - https://de.exac.com/schulter/equinoxe-stemless-shoulder/
- Spain - https://www.exac.es/hombro/equinoxe-stemless-shoulder/
- United Kingdom - https://www.exac.co.uk/shoulder/equinoxe-stemless-shoulder/
- France - https://www.exactech.fr/epaule/equinoxe-stemless-shoulder/
About Exactech
Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, VuMedi, YouTube , Instagram and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005561/en/
Contact information
Priscilla Bennett, APR
VP, Corporate Marketing & Communication
(352) 377-1140
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X19.6.2025 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618511573/en/ [Murata Manufacturing Co., Ltd.] New Chip Ferrite Beads for Automotive In recent years, the use of high-frequency wireless communication in the automotive sector has increased. It is primarily used for content distribution for navigation, audio and other infotainment systems. Improving sensitivity and noise suppression in these advanced high-frequency commu
AV and UAS Denmark Establish Strategic Partnership to Advance Allied UAS Capabilities in Europe18.6.2025 23:30:00 EEST | Press release
AeroVironment, Inc. (“AV”) (NASDAQ: AVAV) today announced it has signed a Memorandum of Understanding (MOU) with Hans Christian Andersen Aiport in Odense, Denmark–home to the UAS Denmark Test Center–to explore joint utilization of the center’s expansive airspace and advanced test facilities. The agreement aims to leverage UAS Denmark’s strategic range and infrastructure to support AV’s uncrewed aircraft system (UAS) demonstration operations, mission training, and customer integration activities across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618380337/en/ JUMP 20 executes a seamless landing on a moving ship (Photo: AV) The collaboration is expected to enable joint research and development (R&D) initiatives and accelerate the growth of the UAS Denmark Test Center as a regional epicenter for advanced UAS innovation, evaluation, and operational readiness. "This MOU represents a significant milestone in expa
Stone Harbor Investment Partners Introduces Emerging Markets Climate Impact Debt Fund18.6.2025 23:05:00 EEST | Press release
Stone Harbor Investment Partners, an investment manager of Virtus Investment Partners, Inc. (NYSE: VRTS), has launched the Stone Harbor Emerging Markets Climate Impact Debt (Bloomberg: STHEMDI) (the “Fund”), a UCITS fund classified as Article 9 under the Sustainable Finance Disclosure Regulation (SFDR) that addresses decarbonization efforts occurring in Emerging Markets (EM) while seeking to deliver attractive long-term total returns for investors. The Fund invests in sustainable debt issued with proceeds dedicated to environmental activities, assets, projects or expenditures, with social bonds also permissible, of EM corporate, sovereign, quasi-sovereign and supranational issuers in hard currency. The Fund, with a sustainable objective to promote the transition towards an environmentally and socially sustainable economy, seeks to outperform the J.P Morgan EM Credit Green, Social and Sustainability Bond Diversified Index (GESSIE EM Credit Div USD Hedged). "Stone Harbor has incorporated
Incyte Announces FDA Approval of Monjuvi ® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma18.6.2025 22:39:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615896694/en/ MONJUVI logo "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without substantial increase in side effects. Based on the data from the inMIND trial of Monjuvi, today’s approval brings to this patient population the first CD-19 and CD20-targeted immunotherapy combination and a potential new treatment standard,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “This second U.S. approval for Monjuvi reinforces our commitment to advancing innovation for the lymp
Bureau Veritas Accelerates its LEAP | 28 Strategy Execution and Evolves its Executive Committee18.6.2025 19:00:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618391984/en/ Hinda Gharbi, CEO Bureau Veritas Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People - and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom